BAM
ATYR

Blueshift Asset Management’s aTyr Pharma ATYR Stock Holding History

Blueshift Asset Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,729
Closed -$95K – 1170
2021
Q4 		$95K Buy
+12,729
New +$106K 0.01% 787

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Blueshift Asset Management's ATYR Position: Q1 2022 in Review

Blueshift Asset Management sold out of aTyr Pharma (ATYR) in Q1 2022, closing a stake of 12,729 shares — an estimated $95K sold.

Blueshift Asset Management first reported a position in ATYR in Q4 2021 and held it in 1 quarter. The position peaked at $95K in Q4 2021. 41 funds tracked by Wall St. Rank hold ATYR as of Q1 2022.

  • Blueshift Asset Management reported no remaining aTyr Pharma position as of Q1 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 12,729 aTyr Pharma shares in Q1 2022, an estimated $95K.
  • Blueshift Asset Management first reported a position in aTyr Pharma in Q4 2021 and held it in 1 quarter.
  • Blueshift Asset Management's aTyr Pharma position peaked at $95K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2022.

Based on Blueshift Asset Management's 13F filing for Q1 2022, filed 12 May 2022.